Obinutuzumab, referred to as GA101, represents a novel monoclonal antibody designed in treat lymphocytic leukemia. This drug targets this surface antigen present on B cells, inducing ADCC and apoptosis. Clinical https://www.targetmol.com/compound/obinutuzumab
Obinutuzumab (GA101): A Comprehensive Overview
Internet - 4 hours ago obinutuzumab388468Web Directory Categories
Web Directory Search
New Site Listings